Quantitation of protein particles in parenteral solutions using micro-flow imaging.

The U.S. and European Pharmacopeias require subvisible (> or =10 and > or =25 microm) and visible particulate testing of therapeutics to ensure their safety and suitability for clinical use. The objective of this article is to compare the sizing and counting accuracies of light obscuration, which is the standard technique used to measure subvisible particulate matter, and Micro-Flow Imaging (MFI), a new imaging-based technology. An immunoconjugate was selected as the model protein for this study since it could be induced to form particulate matter in PBS. Light obscuration was performed as described in USP chapter <788> while MFI measurements were conducted per the manufacturer's procedures. The two techniques yielded similar results when polystyrene standards were analyzed. However, the MFI measurements indicated the presence of significantly more particles in the protein-containing solution compared to the light obscuration measurements. The presence of nonspherical protein particles as well as particles that possess a refractive index similar to the solvent that they are in appear to be detected by MFI, but not by light obscuration, leading to the difference in the results. Imaging-based technologies could aid in developing formulations and processes that would minimize the formation of protein particulates.

[1]  J. Garvan,et al.  THE HARMFUL EFFECTS OF PARTICLES IN INTRAVENOUS FLUIDS , 1964, The Medical journal of Australia.

[2]  T. Sendo,et al.  The evaluation of sizing accuracy of particle counters for parenteral drugs. , 1995, PDA journal of pharmaceutical science and technology.

[3]  Hanns-Christian Mahler,et al.  Induction and analysis of aggregates in a liquid IgG1-antibody formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  D. James,et al.  Insulin precipitation in artificial infusion devices , 1981, Diabetologia.

[5]  Matthew P. Nelson,et al.  Raman Chemical Imaging for Ingredient-specific Particle Size Characterization of Aqueous Suspension Nasal Spray Formulations: A Progress Report , 2007, Pharmaceutical Research.

[6]  H. Lehr,et al.  Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. , 2002, American journal of respiratory and critical care medicine.

[7]  Robert Gurny,et al.  Detection and characterization of protein aggregates by fluorescence microscopy. , 2007, International journal of pharmaceutics.

[8]  B. Zweifach.  STRUCTURAL MAKEUP OF CAPILLARY WALL , 1955, Annals of the New York Academy of Sciences.

[9]  A. Pekar,et al.  Opalescent Appearance of an IgG1 Antibody at High Concentrations and Its Relationship to Noncovalent Association , 2004, Pharmaceutical Research.

[10]  V. Corvari,et al.  A simple method for the detection of insoluble aggregates in protein formulations. , 2007, Journal of pharmaceutical sciences.

[11]  Chung C. Hsu,et al.  Surface Denaturation at Solid-Void Interface—A Possible Pathway by Which Opalescent Participates Form During the Storage of Lyophilized Tissue-Type Plasminogen Activator at High Temperatures , 2004, Pharmaceutical Research.

[12]  Gunner Bw,et al.  Intrvenous fluids: "a solution containing particles must not be used". , 1963 .

[13]  J. Lambert.  Drug-conjugated monoclonal antibodies for the treatment of cancer. , 2005, Current opinion in pharmacology.

[14]  Rajesh Krishnamurthy,et al.  Emerging Analytical Technologies for Biotherapeutics Development , 2008 .

[15]  M. Pikal,et al.  The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone , 1991, Pharmaceutical Research.

[16]  Steven J Shire,et al.  Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. , 2005, Journal of pharmaceutical sciences.

[17]  J. Walker,et al.  Photoinduced particulate matter in a parenteral formulation for bisnafide, an experimental antitumor agent. , 1999, Pharmaceutical development and technology.

[18]  S. Berkowitz.  Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals , 2006, The AAPS Journal.

[19]  J. Brange,et al.  Insulin pumps and insulin quality--requirements and problems. , 2009, Acta medica Scandinavica. Supplementum.

[20]  L. Kirsch,et al.  An assessment of techniques for evaluating the physical stability of parenteral emulsions. , 2003, PDA journal of pharmaceutical science and technology.

[21]  M. Manning,et al.  Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. , 2005, Journal of pharmaceutical sciences.

[22]  D. Leclerc,et al.  Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. , 2007, Virology.

[23]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[24]  F. J. van de Vaart,et al.  Particulate matter determination in LVPs produced in Dutch hospital pharmacies, Part 1: Particle-counting accuracy. , 1997, PDA journal of pharmaceutical science and technology.

[25]  D Schipper,et al.  Comparison of optical electronic inspection and manual visual inspection. , 1978, Journal of the Parenteral Drug Association.

[26]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[27]  T A Barber,et al.  Method evaluation: automated microscopy as a compendial test for particulates in parenteral solutions. , 1989, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[28]  Wei Wang,et al.  Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.

[29]  J. Tamada,et al.  Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. , 1991, Proceedings of the National Academy of Sciences of the United States of America.